Results 81 to 90 of about 1,414 (186)

Recent Advancements in the Treatment of Age‐Related Macular Degeneration

Med Research, Volume 1, Issue 2, Page 151-169, September 2025.
ABSTRACT Age‐related macular degeneration (AMD) is a prevalent cause of visual impairment and blindness among the elderly. AMD can be categorized into two subtypes: “wet” and “dry.” Current treatments for wet AMD mainly involve anti‐vascular endothelial growth factor (VEGF) drugs, and there are three U.S.
Shan Liu, Danyang Lv, Junran Sun, Huixun Jia, Fang Zheng, Felipe Pereira, Siddharth Narendran, Zhenyu Dong, Haiyun Liu, Shunxiang Gao, Peirong Huang   +10 more
wiley   +1 more source

Profile of conbercept in the treatment of neovascular age-related macular degeneration

Drug Design, Development and Therapy, 2015
In developed countries, age-related macular degeneration (AMD) is the leading cause of irreversible blindness in individuals over the age of 65 years. Vascular endothelial growth factor (VEGF) plays a vital role in the formation of neovascular AMD.
Lu, Xinmin, Sun, Xiaodong
openaire   +3 more sources

Clinical Observation of Phacoemulsification Combined with Intravitreal Injection of Conbercept in Cataract Patients with Diabetic Macular Edema

, 2021
Aim. To observe the clinical efficacy and safety of phacoemulsification surgery combined with intravitreal injection of conbercept in cataract patients with DME. Methods. This is a prospective clinical cohort study. Thirty-five cataract patients (49 eyes)
Yuqi Liu, Kaili Tang, Yiping Hu, Lu Lu, Jing Wang, Jinsong Zhang   +5 more
core   +1 more source

Linking preclinical models to clinical realities: VEGF/VEGFR inhibitors and thrombotic microangiopathy in cancer therapy

iMetaOmics, Volume 2, Issue 2, June 2025.
This study investigates the risk of thrombotic microangiopathy (TMA) induced by vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) inhibitors in cancer therapy. Using data from the FDA Adverse Event Reporting System (FAERS), the WHO Global Database for Adverse Drug Reactions (Vigibase), and The Cancer ...
Aimin Jiang, Zhanzhi Li, Ying Liu, Junyi Shen, Quan Cheng, Anqi Lin, Peng Luo, Linhui Wang   +7 more
wiley   +1 more source

Natural products targeting tumour angiogenesis

British Journal of Pharmacology, Volume 182, Issue 10, Page 2094-2136, May 2025.
Abstract Tumour angiogenesis is the formation of new blood vessels to support the growth of a tumour. This process is critical for tumour progression and metastasis, making it an attractive approach to cancer therapy. Natural products derived from plants, animals or microorganisms exert anti‐angiogenic properties and can be used to inhibit tumour ...
Xiaohua Lu, Lara Johanna Friedrich, Thomas Efferth   +2 more
wiley   +1 more source

Intravitreal Conbercept with Grid/Focal Photocoagulation for the Treatment of Diabetic Macular Edema: A Systematic Review and Meta-Analysis

, 2022
Diabetic macular edema (DME) is the main cause of blindness in individuals with diabetes mellitus (DM). This meta-analysis compared the effectiveness and safety of macular grid/focal photocoagulation with and without conbercept in the treatment of DME ...
Xiaoyan Sun, Wei Wei
core   +1 more source

Structural and Vascular Features of Macula Related to the Recurrence of Macular Edema in Central Retinal Vein Occlusion After Anti‐VEGF Therapy

Journal of Ophthalmology, Volume 2025, Issue 1, 2025.
Purpose: To identify the structural and vascular features of the macula related to the recurrence of macular edema (ME) in central retinal vein occlusion (CRVO) after intravitreal anti‐VEGF injections. Methods: This was a cross‐sectional study including CRVO patients without ME and age‐matched individuals.
Dazhuang Ren, Cece Zhao, Gaoxu Wei, Xiaoyun Hou, Chang Li, Zhiqing Li, Akio Oishi   +6 more
wiley   +1 more source

A Randomized Controlled Trial of Conbercept Pretreatment before Vitrectomy in Proliferative Diabetic Retinopathy [PDF]

, 2016
Purpose. To determine the efficacy and safety of preoperative intravitreal conbercept (IVC) injection before vitrectomy for proliferative diabetic retinopathy (PDR). Methods.
Huo Lei, Ruili Wang, Haiyan Zhao, Xiaochun Yang, Ting Zhang, Yan Mei, Jun Liu, Jianbiao Xu   +7 more
core   +1 more source

Current developments of gene therapy in human diseases

MedComm, Volume 5, Issue 9, September 2024.
Gene therapy has seen remarkable advancements in recent decades, demonstrating its immense potential in treating a wide range of genetic and acquired diseases. Several AAV gene therapy products have been introduced to the market, addressing various conditions.
Fanfei Liu, Ruiting Li, Zilin Zhu, Yang Yang, Fang Lu   +4 more
wiley   +1 more source

Effect and factors associated with reactivation after intravitreal conbercept or aflibercept in retinopathy of prematurity

European Journal of Medical Research
Background To evaluate the effect and factors associated with the reactivation of retinopathy of prematurity (ROP) after intravitreal conbercept or aflibercept.
Chunling Huang, Weikang Zou, Wenbei Ma, Jiali Li, Yichen Bai, Rong Wu, Qiqi Li, Qi Fang, Wenna Chen, Xiaohe Lu, Songfu Feng   +10 more
doaj   +1 more source